Edgewise Therapeutics adopts 2024 Inducement Plan, reserving 2M shares for new hires

Edgewise Therapeutics, Inc.

Board adopted 2024 Inducement Equity Incentive Plan effective August 10, 2024, reserving 2,000,000 shares of common stock.
Plan allows grants of nonstatutory stock options, SARs, restricted stock, RSUs, and performance awards as hiring inducements.
Adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4) – limited to new employees or merger hires.
Terms are substantially similar to the 2021 Equity Incentive Plan; no Exchange Program is permitted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.